◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

HomeAll stocks0-9 › 2627

Ab&B Bio-Tech CO., LTD. JS (2627) Financial History

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Drug Manufacturers - Specialty & Generic · DATA UPDATED 2026-08-10

Ab&B Bio-Tech CO., LTD. JS (2627) operates in the Drug Manufacturers - Specialty & Generic industry and is headquartered in Taizhou, China with about 583 employees. Its market capitalization is roughly CNY 12 billion. In the fiscal year ended 2024-12-31, 2627 reported CNY 260M in revenue and (CNY 259M) in net income.

Ab&B Bio-Tech CO., LTD. JS researchs, develops, manufactures, and sells vaccines and biological preparations that provide active immunity against diseases.

Interactive charts & full statements →

2627 Revenue & Earnings History — Annual Income Statement

Income statement2024-12-312023-12-31
Total RevenueCNY 260MCNY 52M
Gross ProfitCNY 152M(CNY 20M)
Operating Income (EBIT)(CNY 229M)(CNY 423M)
Net Income(CNY 259M)(CNY 425M)

CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

2627 Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement2025-06-302025-03-31
Total RevenueCNY 71MCNY 0M
Gross ProfitCNY 64M(CNY 4M)
Operating Income (EBIT)(CNY 30M)(CNY 76M)
Net Income(CNY 34M)(CNY 87M)

CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

2627 Free Cash Flow History

2627 Balance Sheet History

Balance sheet2024-12-312023-12-31
Total AssetsCNY 1.6BCNY 1.1B
Total LiabilitiesCNY 1.5BCNY 756M

CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive 2627 viewer.

Other Companies in Drug Manufacturers - Specialty & Generic

← 2625All “0-9” companies2628 →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.